Skip to main content

Table 5 Follow-up midterm results

From: Should bioprostheses be considered the valve of choice for dialysis-dependent patients?

Complications Group B(n = 36) Group M(n = 33) P Value
Valve-related 6(16.7%) 11(33.3%) <0.05
 Bleeding event 0 2(6.1%) <0.05
 Thromboembolism 0 3(9.1%) <0.05
 PVE 2(5.6%) 2(6.1%) NS
 Valve deterioration 0 0 NS
 perivalvular leak 1(2.8%) 1(3.0%) NS
 Reoperation 3(8.3%) 3(9.1%) NS
Cardiac death 2 (5.6%) 2(6.1%) NS
 Heart failure 1(2.8%) 1(3.0%) NS
 Arrhythmia 1(2.8%) 1(3.0%) NS
Non-cardiac death 5(13.9%) 5(15.2%) NS
 Malignancy 3(8.3%) 2(6.1%) <0.05
 Other 2(5.6%) 3(9.1%) <0.05
Late mortality 7(19.4%) 7(21.2%) NS
  1. Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant. PVE, prosthetic valve endocarditis.